Abstract
AbstractAlthough the pathogenesis of Alzheimer’s disease (AD) is still unknown, the molecular pathological phenomena is clear, mainly due to mitochondrial dysfunction and central nervous system inflammation caused by imbalanced antioxidant capacity and synaptic dysfunction, so antioxidant therapy is still the preferred treatment for AD. However, although antioxidant enzymes have high catalytic efficiency, the substrate spectrum is narrow; Antioxidants have wider range of effects, but their efficiency is low. Since the antioxidant defense system in high-grade organisms is composed of both enzymatic and non-enzymatic systems, therefore we synthesized a metal-organic framework (MOF) with superoxide dismutase activity, and depending on the interface potential effect, curcumin was loaded to construct a synergistic antioxidant treatment system. More importantly, due to the complementary surface electrostatic potential between MOF and curcumin, the system exhibited both good antioxidant activity and efficient β-amyloid plaque scavenging ability, which slowed down the cognitive dysfunction in the brain of AD mice.
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Xu, H. et al. ADpred: A non-invasive model for three types of dementia and mild cognitive impairment. Innov. Med. 1, 100026 (2023).
2. Fu, W. Y. & Ip, N. Y. The role of genetic risk factors of Alzheimer’s disease in synaptic dysfunction. Semin. Cell Dev. Biol. 139, 3–12 (2023).
3. Zhao, D. et al. A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer’s disease. Innovation 2, 100160 (2021).
4. Cheng, Y. et al. Physiological beta-amyloid clearance by the liver and its therapeutic potential for Alzheimer’s disease. Acta Neuropathol. 145, 717–731 (2023).
5. Jiang, Y. et al. MiR-539-5p decreases amyloid beta-protein production, hyperphosphorylation of tau and memory impairment by regulating PI3K/Akt/GSK-3beta pathways in APP/PS1 double transgenic mice. Neurotox. Res. 38, 524–535 (2020).